SG Americas Securities LLC Purchases 12,544 Shares of Bio-Rad Laboratories, Inc. $BIO

SG Americas Securities LLC grew its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 195.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,958 shares of the medical research company’s stock after purchasing an additional 12,544 shares during the period. SG Americas Securities LLC’s holdings in Bio-Rad Laboratories were worth $5,744,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Royal Bank of Canada grew its position in Bio-Rad Laboratories by 25.2% during the first quarter. Royal Bank of Canada now owns 30,310 shares of the medical research company’s stock worth $7,382,000 after buying an additional 6,100 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Bio-Rad Laboratories by 45.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 105,006 shares of the medical research company’s stock valued at $25,575,000 after acquiring an additional 32,874 shares during the last quarter. Empowered Funds LLC boosted its position in shares of Bio-Rad Laboratories by 14.8% during the 1st quarter. Empowered Funds LLC now owns 1,547 shares of the medical research company’s stock valued at $377,000 after acquiring an additional 199 shares during the last quarter. Jane Street Group LLC grew its holdings in shares of Bio-Rad Laboratories by 95.3% during the first quarter. Jane Street Group LLC now owns 37,383 shares of the medical research company’s stock worth $9,105,000 after purchasing an additional 18,239 shares in the last quarter. Finally, Creative Planning grew its holdings in shares of Bio-Rad Laboratories by 22.7% during the second quarter. Creative Planning now owns 2,797 shares of the medical research company’s stock worth $675,000 after purchasing an additional 518 shares in the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on BIO shares. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Trading Up 3.0%

Shares of BIO stock opened at $278.54 on Wednesday. The business has a 50-day moving average price of $279.88 and a two-hundred day moving average price of $298.57. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The firm has a market cap of $7.52 billion, a P/E ratio of 9.98 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). The firm had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. Bio-Rad Laboratories’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.90 earnings per share. Equities analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.